BAYER AG SPON ADR REP 1 NPV (BAYRY)

108.75
0.56 0.51
OTC
Prev Close 109.31
Open 108.68
Day Low/High 108.21 / 108.92
52 Wk Low/High 91.53 / 125.20
Volume 81.83K
Exchange OTC
Shares Outstanding 826.95B
Market Cap 83.95B
Div & Yield N.A. (N.A)

Latest News

European Pharma Shares Hammered After Trump Press Conference Attack

European Pharma Shares Hammered After Trump Press Conference Attack

European health care and pharmaceutical company shares were hit hard Thursday after President-elect Donald Trump accused some firms of 'getting away with murder' in his Wednesday press conference.

'Stage Is Set' for M&A to Continue in 2017

'Stage Is Set' for M&A to Continue in 2017

Elizabeth Lim, Mergermarket America head research editor, expects further energy consolidation and increased media mergers in 2017.

Analysts Mixed on Health Care Stocks in the New Year

Analysts Mixed on Health Care Stocks in the New Year

While there is deep uncertainty about how politics will affect the health care sector in the new year, analysts seem excited about some opportunities in pharmaceuticals.

European Stocks Mixed, Oil Rises Higher in Holiday-Thinned Trading

European Stocks Mixed, Oil Rises Higher in Holiday-Thinned Trading

European stocks opened a holiday-thinned session with caution as U.S. dollar strength continues to drive sentiment.

European Stock Markets Rise as Investors Buy Back Risk Assets; London Leads

European Stock Markets Rise as Investors Buy Back Risk Assets; London Leads

U.K. stocks are buoyed by retail sales at a 14-year high, prompting a resurgence of consumer and real estate stocks.

European Stocks Slide as Bond Yields, U.S. Dollar Creep Higher

European Stocks Slide as Bond Yields, U.S. Dollar Creep Higher

European stocks are in the red Wednesday as government bond yields edge higher amid the global inflation trade.

Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit

Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit

A sale or spinoff of this business will likely get the attention of competitors that want to increase their over-the-counter product units.

Roche's Haemophilia Drug Difficulties Has Rivals Looking for an Edge

Roche's Haemophilia Drug Difficulties Has Rivals Looking for an Edge

Pfizer, Bayer, Shire are among rivals bracing for Roche's ACE910.

Will Seed and Farm-Chemical Producers Sow Our Food Needs in Asia?

Will Seed and Farm-Chemical Producers Sow Our Food Needs in Asia?

A WWF report shows how fragile our hold on the world's ecology is. Does Asia represent the future of food production?

It's Not Too Late to Buy Time Warner, Monsanto, Other M&A Targets

It's Not Too Late to Buy Time Warner, Monsanto, Other M&A Targets

Some of the biggest deals already announced on Wall Street are currently pricing in hefty premiums for investors willing to take the risk.

Four Stock Picks for 2017

Four Stock Picks for 2017

Don't sell these shares just yet.

Bayer Beats Estimates as Drugs Gain While Crops Stall

Bayer Beats Estimates as Drugs Gain While Crops Stall

Strong drug sales allow the German group to increase its full-year earnings forecast, while wilting crop science revenue pose more questions about the wisdom of buying Monsanto.

European Stocks Slide As Oil Falls Back and Earnings Disappoint

European Stocks Slide As Oil Falls Back and Earnings Disappoint

U.K. lender Lloyds falls after a third-quarter profit miss, while luxury goods maker Kering surges.

Cramer: Regulators Are Looking to Kill, Not Bless Mega Mergers

Cramer: Regulators Are Looking to Kill, Not Bless Mega Mergers

This is new doctrine having to do with innovation and the stifling of innovation to create new products.

Syngenta Warns of Delay in $43 Billion Takeover by ChemChina

Syngenta Warns of Delay in $43 Billion Takeover by ChemChina

The Swiss fertilizers maker says regulators in the EU and elsewhere have demanded more information.

Don't Succumb to the Buzz of the Mega Merger

Don't Succumb to the Buzz of the Mega Merger

Results have shown that many major "blockbuster" deals aren't blockbuster investments later.

Cramer: Don't Buy Either AT&T or Time Warner on Merger News

Cramer: Don't Buy Either AT&T or Time Warner on Merger News

Regulatory issues will weigh on this deal, because of populist politics.

European Week Ahead: GDP Data, Consumer Poll to Measure Brexit Damage

European Week Ahead: GDP Data, Consumer Poll to Measure Brexit Damage

Forward-looking purchasing managers' indices and earnings from beleaguered lender Deutsche Bank feature among the other release highlights.

Four Stocks That Could Power Your Portfolio in 2017

Four Stocks That Could Power Your Portfolio in 2017

Here is why CBS, Constellation Brands, Monsanto and Aetna will be winners in 2017.

Why Larry Fink May Be the Trustbusters' Next Target

Why Larry Fink May Be the Trustbusters' Next Target

Experts say mutual funds' stakes across an industry can thwart competition and that anti-trust regulators should require them to pare their holdings in that case.

Profit From the M&A Wave With ETFs, Mutual Funds

Profit From the M&A Wave With ETFs, Mutual Funds

Buy mutual funds and exchange-traded funds that buy shares of those companies involved in takeovers.

Oil, Yellen and World GDP Growth: How to Trade the Week Ahead

Oil, Yellen and World GDP Growth: How to Trade the Week Ahead

Conditions seem ripe for continued upward momentum in stocks, as long as the Federal Reserve or unexpected shocks don't get in the way.

Bayer Raises Drug Sales Targets and Leaves Monsanto Combination Trailing

Bayer Raises Drug Sales Targets and Leaves Monsanto Combination Trailing

CEO Werner Baumann increases sales and margin forecasts for pharmaceuticals and insists Monsanto deal will deliver growth and improved profit.

Bayer, Monsanto Brace for Long Climb With Regulators

Bayer, Monsanto Brace for Long Climb With Regulators

Despite intense opposition from farm groups and skepticism from government enforcers, the merging crop technology giants say they expect to win approval by end of 2017.

Crude Selloff Pulls Stocks Lower but Apple Saves Nasdaq

Crude Selloff Pulls Stocks Lower but Apple Saves Nasdaq

Another selloff on commodity markets on Wednesday contributed to stock losses throughout the day.

Stocks Waver as Oil Tumbles but Apple Lifts Nasdaq

Stocks Waver as Oil Tumbles but Apple Lifts Nasdaq

Stocks lose highs by mid-afternoon Wednesday as a selloff in crude resumes.

European Stock Markets Mixed Amid Weakness in Luxury Goods

European Stock Markets Mixed Amid Weakness in Luxury Goods

German Dax leads the board with 0.4% gain.

Stocks Add to Gains as Apple Boosts Dow, Crude Fluctuates

Stocks Add to Gains as Apple Boosts Dow, Crude Fluctuates

Stocks add to slight gains on Wednesday as Wall Street stabilizes after three days of extreme swings.